Gordonia species are emerging pathogens that are often misidentified as Rhodococcus or Nocardia species but are reliably distinguished by 16S ribosomal RNA gene sequencing. We present a case series of 6 episodes of catheter-associated infection caused by Gordonia species in 5 patients seen at a tertiary care pediatric hospital and describe the management and outcomes of this infection in adults and children.
Gordonia species are emerging pathogens that are often misidentified as Rhodococcus or Nocardia species but are reliably distinguished by 16S ribosomal RNA gene sequencing. We present a case series of 6 episodes of catheter-associated infection caused by Gordonia species in 5 patients seen at a tertiary care pediatric hospital and describe the management and outcomes of this infection in adults and children.
Gordonia species are nocardioform actinomycetes and environmental organisms [1] and have been described as human pathogens only in isolated case reports and a single case series [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . The natural history, optimal treatment, and outcomes of infection are not well described in adults, and only a single episode has been previously reported in a child [2] .
Gram-positive bacilli, including Gordonia species, are often difficult to identify at both a genus and species level by conventional microbiologic culture and biochemical analysis [13, 14] . When isolated in culture, Gordonia species may be dismissed as contaminating diptheroids or misidentified as other gram-positive bacilli, such as Rhodococcus or Nocardia species [7, 12] . DNA sequencing provides an opportunity for definitive identification. By incorporating 16S rRNA gene sequencing into the identification protocol for gram-positive bacilli, we are in-creasingly recognizing Gordonia species as invasive pathogens. We present a case series of 6 episodes of catheter-associated infection caused by Gordonia species in 5 pediatric patients and describe the management and outcomes of these infections.
Methods. The institutional review boards of Intermountain Healthcare (Salt Lake City, UT) and the University of Utah (Salt Lake City, UT) approved this study. Patients with Gordonia infection were identified using the Intermountain Healthcare computerized Electronic Data Warehouse, which contains clinical, laboratory, and microbiological data for all patients in the Intermountain Healthcare system. Children aged р18 years who had a blood or CSF culture result positive for Rhodococcus, Nocardia, or Gordonia species from January 2001 through May 2006 were identified. The medical records of children with Gordonia infection were abstracted for demographic and clinical data, including immune status, presence of an implanted catheter, evidence of disseminated disease, antibiotic therapy, and outcome. Antibiotic susceptibilities were based on the Clinical and Laboratory Standards Institute broth microdilution breakpoints for Nocardia species and other aerobic actinomycetes [15] .
From January 2001 through December 2004, all gram-positive bacilli were identified using conventional microbiologic methods at the Primary Children's Medical Center (Salt Lake City, UT) clinical microbiology laboratory, and sequencing was obtained only by physician request. During the final year of the review period, all gram-positive bacilli that were not identified to the species level by routine biochemistry were identified using 16S rRNA gene sequencing at a national reference laboratory (Associated Regional and University Pathologists Laboratories, Salt Lake City, UT) [14] .
Results. Eight patients were identified to have invasive Rhodococcus, Nocardia, or Gordonia infections. Conventional microbiology identified 5 bloodstream isolates as Rhodococcus species, 2 bloodstream isolates as Nocardia species, and 1 CSF isolate as Gordonia species. Four of the 5 Rhodococcus isolates and both of the Nocardia isolates underwent 16S rRNA gene sequencing. 16S rRNA sequencing confirmed that 3 of the 4 Rhodococcus isolates and 1 of the 2 Nocardia isolates were actually Gordonia species (3 Gordonia terrae and 1 Gordonia otitidis, a newly recognized species [16] ). The 1 Gordonia isolate identified by conventional microbiologic examination also underwent sequencing and was confirmed to be Gordonia bronchialis. In addition, 1 organism that was identified as a grampositive bacillus was sequenced at the request of the treating physician and identified as G. terrae. These findings led to the Buchman et al. [6] , Gil-Sande et al. [7] , Kempf et al. [8] , Sng et al. [9] , Verma et al. [10] , and Pham et al. [11] . Three reference strains are included from Drancourt et al. [2] .
identification of 6 episodes of invasive Gordonia infection (5 episodes of bacteremia and 1 episode of ventriculitis) in 5 children.
The clinical features of patients with Gordonia infection are summarized in table 1. All patients had an implanted catheter (5 had a central venous catheter, and 1 had an intracranial shunt) as their primary risk for infection. In addition, 3 patients had congenital or acquired immunodeficiencies (1 had hypogammaglobulinemia, and 2 had a malignancy).
For all cases, gram-positive bacilli were isolated in pure culture from blood or CSF samples and identified by 16S sequence as Gordonia species. Blood culture results were persistently positive for Gordonia species in 3 children (median duration with a positive culture result, 9 days). For 4 of 5 children, removal of the implanted device was necessary because of persistence of positive culture results or disseminated disease.
All patients had evaluations for remote infection, and 2 of 5 children had radiographic evidence of disseminated disease. In both patients, CT of the chest demonstrated multiple parenchymal nodules in the lungs that were consistent with septic emboli, and in 1 patient, the echocardiogram was suggestive of endocarditis. In both patients, the CT and echocardiographic findings resolved with treatment directed at the Gordonia species isolated from the blood sample.
All infections were successfully treated with combination antibiotic therapy. All patients received antibiotics for at least 4-6 weeks, except for 1 patient who was initially treated for 2 weeks. This patient had a recurrence of infection 7 months after initial treatment and was successfully treated again for 6 weeks. There was no infection-related mortality.
Discussion. This study reports 6 cases of Gordonia infection in children. It is, to our knowledge, the largest pediatric case series to date and the first report of a Gordonia infection in a neonate. All 6 Gordonia isolates were identified by gene sequence analysis during the last year of our study period. This implies either that Gordonia species are emerging pathogens in pediatric patients or, more likely, that they are newly recognizable pathogens because of improved diagnostic technology.
All children with Gordonia infection in our series had an implanted catheter. A review of the 15 previously reported cases of invasive Gordonia infection [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] demonstrates that 12 (80%) of the cases were likely to have been cathether-related (11 bacteremia cases [4-6, 8, 10, 11] and 1 brain abscess at the site of a surgical drain placement [2] ). In 7 (58%) of the 12 reported catheter-associated cases, the catheter was removed, and in all 12 cases, the infection cleared. In our series, 4 of 5 children required central venous catheter or intracranial shunt removal for clearance of infection. We recommend catheter removal for the treatment of Gordonia infection in children.
Most case reports of Gordonia infection in adults have involved patients with immune dysfunction. Twelve of the 15 previously reported cases occurred in immunocompromised patients; 9 cases involved malignancy [2, 4, 5, [7] [8] [9] [10] [11] . In our series, 3 of 5 patients had underlying immunocompromise (2 due to malignancy), suggesting that immunocompromise is likely to be a risk factor among both children and adults.
Two patients in our series had dissemination of their disease to the lungs at the time of initial diagnosis, and 1 patient had presumed endocarditis. Two cases of Gordonia species-related endocarditis have been described previously [4, 10] . Combined with the case in our series, the proportion of reported cases of Gordonia species-related endocarditis is 3 (14%) of 21 cases. We suggest that evaluation for dissemination should be indicated for all patients with catheter-related infection caused by Gordonia species. Table 2 summarizes antibiotic susceptibility data for our isolates, as well as data for isolates that were previously published (24 total isolates) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . These data suggest that initial therapy for Gordonia infection could include a carbapenem or a fluoroquinolone in combination with an aminoglycoside. Carbapenems and aminoglycosides are also effective against Rhodococcus and Nocardia species [17, 18] . Eighty-nine percent of isolates were susceptible to vancomycin, which is often used as initial therapy for gram-positive bacilli and in the treatment of Rhodococcus infection [18] . However, trimethoprim-sulfamethoxazole, which is often used to treat Nocardia infection [17] , had poor activity against Gordonia species, with only 65% of tested isolates being susceptible. Linezolid, which is active in vitro against Nocardia species [17] , was tested in our series and in 1 other case report; all 7 Gordonia isolates tested were susceptible.
16S rRNA gene sequencing was crucial for the identification of the Gordonia infections presented in this series. The availability of this technology allowed us to recognize Gordonia infections that otherwise would have been attributed to Rhodococcus or Nocardia species. Our study is limited, because we did not sequence all gram-positive bacilli during the study period. It is possible that there were other Gordonia infections, particularly early in the study, that were dismissed as diptheroid contaminants or unidentified gram-positive bacilli. Despite this limitation, this pediatric series remains the largest to date. We conclude that Gordonia species may be emerging or increasingly recognized pathogens in pediatric patients with indwelling catheters, especially in immunocompromised pediatric patients. In addition, we recommend incorporating 16S rRNA gene sequencing, which is available at national reference laboratories, into the standard identification procedure for clinically significant gram-positive bacilli that are difficult to identify using conventional techniques. We believe that this will result in improved identification of Gordonia species, as well as in the ability to offer directed therapy and, ultimately, in improved clinical outcomes.
